Sponsor:
Children's Hospital of Philadelphia
Code:
NCT02356653
Conditions
Leukemia
Inborn Errors of Metabolism
Bone Marrow Failure Syndromes
Immunodeficiencies
Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome
Eligibility Criteria
Sex: All
Age: 0 - 30
Healthy Volunteers: Not accepted
Interventions
Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)
Brief summary:
Conditions
Leukemia
Inborn Errors of Metabolism
Bone Marrow Failure Syndromes
Immunodeficiencies
Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome
Study ID
NCT02356653
Start date
Dec, 2013
Status verified date
Feb, 2026
Completion date
Jan, 2030
Anticipated
Primary completion date
Jan, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 0 - 30
Healthy Volunteers: Not accepted
Enrollment
100 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Expanded access to CliniMACs device for T cell depletion
Interventions
Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)
Primary outcome measure
Central contacts
Locations
Children's Hospital of Philadelphia
Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contacts
Principal Investigator:
Timothy Olson, MD, PhD
Sponsor
Children's Hospital of Philadelphia
Last update posted
Feb 20, 2026
Last verified
Feb, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Children's Hospital of Philadelphia on 2026-02-20.